{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.480","pValueComment":"P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.064","pValueComment":"P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.116","pValueComment":"P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.201","pValueComment":"P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.70","value":"-8.4"},{"groupId":"OG001","spread":"13.50","value":"-11.3"},{"groupId":"OG002","spread":"10.45","value":"-12.2"},{"groupId":"OG003","spread":"12.97","value":"-14.7"},{"groupId":"OG004","spread":"12.31","value":"-7.6"}]}],"title":"TJC - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and standard deviation (SD) were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"12.60","value":"-12.4"},{"groupId":"OG002","spread":"9.54","value":"-14.0"},{"groupId":"OG003","spread":"11.23","value":"-17.5"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"TJC - Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.24","value":"-8.1"},{"groupId":"OG001","spread":"9.03","value":"-8.9"},{"groupId":"OG002","spread":"6.49","value":"-9.6"},{"groupId":"OG003","spread":"8.88","value":"-10.4"},{"groupId":"OG004","spread":"7.97","value":"-6.7"}]}],"title":"SJC - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"8.16","value":"-10.0"},{"groupId":"OG002","spread":"6.42","value":"-10.5"},{"groupId":"OG003","spread":"7.29","value":"-12.2"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"SJC - Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Parts A and B and had TJC and SJC evaluated at analysis time points. LOCF was used to impute missing post-baseline values","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 12 and 24","title":"Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)","type":"SECONDARY","unitOfMeasure":"number of joints"}